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Background: Neuromyelitis optica (NMO) is a severe demyelinating disorder of the central nervous system (CNS)
associated with the presence of an autoimmune antibody response (AQP4-IgG) against the water channel
aquaporin-4 (AQP4). It remains unclear whether pathologic AQP4-IgG in the CNS is produced entirely by peripheral
plasma cells or is generated in part by infiltrating B cells. To determine the overlap of AQP4-IgG idiotypes between
the CNS and periphery, we compared the immunoglobulin G (IgG) transcriptome of cerebrospinal fluid (CSF)
plasmablasts with the CSF and serum IgG proteomes in 7 AQP4-seropositive NMO patients following exacerbation.
Methods: CSF variable region Ig heavy- (VH) and light-chain (VL) transcriptome libraries were generated for each
patient from CSF plasmablasts by single cell sorting, reverse transcriptase polymerase chain reaction (RT-PCR), and
DNA sequencing. Recombinant antibodies were generated from clonally expanded, paired VH and VL sequences
and tested for AQP4-reactivity by cell-binding assay. CSF and serum IgG fractions were searched for sequences that
matched their respective CSF IgG transcriptome. Matching peptides within the same patient’s CSF and serum IgG
proteomes were also identified.
Results: In each NMO patient, we recovered CSF IgG VH and VL sequences that matched germline-mutated IgG
protein sequences from the patient’s CSF and serum IgG proteomes. Although a modest variation was observed
between patients, the overlap between the transcriptome and proteome sequences was found primarily, but not
exclusively, within the CSF. More than 50% of the CSF IgG transcriptome sequences were exclusively found in the
CSF IgG proteome, whereas 28% were found in both the CSF and blood IgG proteome, and 18% were found
exclusively in the blood proteome. A comparable distribution was noted when only AQP4-specific IgG clones were
considered. Similarly, on average, only 50% of the CSF IgG proteome matched corresponding peptide sequences in
the serum.
Conclusions: During NMO exacerbations, a substantial fraction of the intrathecal Ig proteome is generated by an
intrathecal B cell population composed of both novel and peripherally-derived clones. Intrathecal CSF B cell clones
may contribute to NMO disease exacerbation and lesion formation and may be an important target for preventative
therapies.
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Neuromyelitis optica (NMO) is a severe central nervous
system (CNS) autoimmune disorder with predilection
for the optic nerves and spinal cord [1]. Specific to the
disease is an autoimmune population of B cells that pro-
duces autoantibodies (AQP4-IgG) against the water chan-
nel aquaporin-4 (AQP4) [2-5]. Although controversial,
serum and cerebrospinal fluid (CSF) titers of AQP4-IgG
have been shown to correlate loosely with clinical dis-
ease activity and disability in affected individuals. Serum
AQP4-IgG titers are increased at the nadir of exacerba-
tions, and higher serum and CSF AQP4-IgG titers are
observed in patients with severe lesions [6,7]. Conversely,
clinical improvement has been correlated with a decrease
in CSF AQP4-IgG titers [8].
The relationship between serum and CSF titers of
AQP4-IgG and the presence of intrathecal AQP4-IgG
production, however, remains unclear. Several studies
have suggested that AQP4 autoantibodies are passively
transferred from serum to CSF [6,8-10]. In contrast,
other studies have documented intrathecal synthesis of
AQP4-IgG [3,8,11]. Klawiter and colleagues [12] also
reported three cases in which AQP4-IgG was restricted
to the CSF, but this study remains controversial due to
methodological issues. Using standard clinical labora-
tory methods, CSF oligoclonal IgG bands have been in-
frequently observed in NMO patients; and if present,
the level of intrathecal IgG synthesis was low, transient,
and restricted to acute relapses [9,11,13].
The identification of clonally expanded CSF plasma-
blasts expressing AQP4-IgG in an NMO patient [3] sug-
gests that intrathecal B cell populations may contribute
to CSF AQP4-IgG and disease pathogenesis. To study
the origin of CSF AQP4-IgG, we compared the immu-
noglobulin G (IgG) transcriptome of CSF plasma cells
with the IgG CSF and serum proteomes in seven AQP4-
seropositive NMO patients. The overlapping sequences
indicate that intrathecal antibody production contributes
measurably to the generation of CSF AQP4-IgG.
Methods
Patients
AQP4-seropositive NMO or NMO spectrum disease
(NMOSD) patients experiencing an acute exacerbation
were recruited at the University of Colorado (ON10-03;
ON09-03; ON10-01; ON07-05; ON08-08; ON11-04)
and the Technische Universität München (TUM09-527).
CSF analysis was performed within 84 days of symptom
onset (median: 28 days; range 1 to 84 days). Diagnoses
were made according to published criteria [14,15]. Patient
CSF was obtained as a part of their standard clinical
evaluation; informed consent was obtained prior to study
participation. The ethics committee of the University of
Colorado Denver and Technische Universität Münchenapproved the scientific use of CSF and serum samples.
Biologic samples were processed and stored according
to consensus guidelines [16]. As prior work has reported
decreased serum AQP4-IgG titers following treatment
with rituximab and methylprednisolone [7], CSF was col-
lected prior to or 4 weeks following steroid administration
(ON07-5; ON08-8). Patient TUM09-527 was treated with
rituximab; all other patients were untreated at the time of
exacerbation. Table 1 shows the CSF parameters and the
calculated AQP4 antibody index (AQP4-AI). AQP4-AI
was determined as described previously [17]. No patient
received intravenous immunoglobulin (IVIG) treatment,
had a chronic infection, or was noted to have a monoclo-
nal gammopathy by serum electrophoresis or proteomic
analysis.
Single cell analysis of B cells, antibody production and
AQP4 reactivity
CSF IgG variable region heavy- (VH) and light-chain (VL)
sequences were recovered from CD19-CD138+ plasma-
blasts by single cell fluorescent-activated cell sorting
(FACS), reverse transcriptase PCR (RT-PCR), and DNA
sequencing as described previously [18]. Recombinant
antibodies were produced in HEK293 cells (Invitrogen,
Carlsbad, CA, USA; R620-07) as described previously
[3] and reactivity was tested via a quantitative cell-
binding immunofluorescence assay using a U87MG
permanent cell line expressing M23-AQP4 [19].
Mass spectrometry of CSF and serum IgG
CSF and serum IgG (0.5 to 2.0 ml) was applied to pro-
tein A sepharose columns (GE Healthcare, Pittsburgh,
PA, USA) and purified according to the manufacturer’s
instructions. Protein concentrations were determined by
bicinchoninic acid (BCA) Protein-Assay (Pierce, Thermo
Fisher, Waltham, MA, USA), and the purity analyzed by
sodium dodecyl sulfate polyacrylamide electrophoresis.
Excised heavy- and light-chain gel pieces were destained
in ammonium bicarbonate/50% acetonitrile (ACN) and
dehydrated in 100% acetonitrile. Disulfide bonds were
reduced by dithiothreitol, and cysteine residues were
alkylated with iodoacetamide. Heavy-chain proteins were
digested with trypsin, light chains with trypsin and S.
aureus V8 protease (Glu-C). Following digestion, the
tryptic mixtures were extracted in 1% formic acid/50%
acetonitrile). Samples were analyzed on a linear trap quad-
ropole (LTQ) Orbitrap Velos mass spectrometer (Thermo
Fisher Scientific, Waltham, MA, USA) coupled to an
Eksigent nanoLC-2D system (Framingham, MA, USA)
through a nanoelectrospray LC-MS interface using a
90-minute gradient from 6 to 40% ACN. Peptide frag-
mentation was performed in a higher energy collisional
dissociation cell with normalized collision energy of 40%,
and tandem mass spectra were acquired in the Orbitrap
Table 1 Results of routine cerebrospinal fluid (CSF) examination
Normal range ON10-03 ON09-03 ON10-01 ON07-05 ON08-08 ON11-04 TUM09-527
Cell count (cells/μl) 0 to5 4 9a 16a 19a 5 2 15a
Albumin serum 3,500 to5,200 4,140 4,330 4,300 4,030 4,100 3,530 3,900
(mg/dl)
Albumin CSF 0 to 35 32 23 20 38a 24 8 38a
(mg/dl)
Albumin Quotient 0.0 to 9.0 7.72 5.31 4.65 9.43a 5.85 2.27 9.74a
(x103)
IgG serum 768 to 1,632 462 2,570a 634 1,460 2,060a 1,210 965
(mg/dl)
IgG CSF 0.0 to 6.0 4.1 6.3a 1.7 6.8a 4.9 1.4 4.7
(mg/dl)
IgG Quotient 0.0 to 7.8 8.87a 2.45 2.68 4.65 2.38 1.16 4.87
(x103)
IgG Intrathecal Fraction (%) NA 34 0 0 0 0 0 0
IgG Index 0.28 to 0.66 1.15a 0.46 0.58 0.49 0.41 0.51 0.51
OCBs - + - - - - - -
AQP4 Index (<1.5) 1.57a 0.56 1.45 2.0a 0 0 0.86
(AQP4-AI)
aIndicates abnormal values; NA, not available.
CSF erythrocytes averaged 2.3 cells/μl (range 0 to 11 cells/μl).
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Xcalibur software (version 2.0.6; Waltham, MA, USA).Database searching, protein identification
Tandem mass (MS/MS) spectra were converted into mgf
files using an in-house script. Mascot (version 2.2; Matrix
Science Inc., London, UK) was used to perform database
searches against the Swiss-Prot database and a database
containing translated CSF B cell transcriptome repertoires.
Peptide tolerance was set at ± 15 ppm with an MS/MS
tolerance of ± 0.1 Da from spectra. Full trypsin specificity
was required and one missed cleavage was allowed; carba-
midomethylation on cysteine was defined as a fixed modi-
fication; methionine oxidation, N-terminal pyroglutamic
acid formation and N-terminal (protein) acetylation were
defined as variable modifications in the database search.
Scaffold (version4, Portland, OR, USA) was used to valid-
ate MS/MS based peptide and protein identifications. Pep-
tide identifications were accepted at a > 95.0% probability,
protein identifications at a > 99.0% probability.Alignment of IgG transcriptome and proteome sequences
To search for an overlap between IgG transcriptome se-
quences and IgG proteome peptides, recovered peptides
were aligned to the same patient’s transcriptome sequen-
ces using Scaffold software (Portland, OR, USA). Peptides
were considered unique when they were identical to the
somatically mutated cDNA sequence of the VH or VLsequence (Figure 1). To determine the extent of overlap
between CSF and blood Ig sequences, peptides were
aligned to the human protein database (Swiss-Prot),
and matching IgG tested for mutations to the germline
using Vbase2 (http://www.vbase2.org/).
Results
Analysis of IgG transcriptomes and proteomes
We generated subject-specific variable region VH and
VL repertoires from seven NMO and NMOSD patients
and in conjunction assessed IgG VH and VL peptide li-
braries from the patients’ CSF and serum. Using the CSF
VH and VL transcriptome repertoires as databases, we
examined the serum and CSF IgG proteomes for matching
unique sequences defined as peptides perfectly match-
ing somatically-mutated CSF transcriptome sequences
(Figure 1). No unique serum or CSF IgG peptides matched
CSF transcripts from another NMO patient. On average,
27% (range 15 to 44%) of the unique heavy- and light-
chain CSF transcriptome sequences could be recovered
in IgG peptides. A slightly higher percentage of tran-
scripts corresponding to known AQP4-specific anti-
bodies (mean 37%; range 0 to 60%) were recovered in
the IgG proteomes (Table 2). The efficiency of matching
CSF IgG transcripts with peptides in the CSF or serum
proteome did not correlate with evidence of blood-CSF
barrier disruption, although the maximal recovery of
matching peptides occurred in subject ON10-03 who had
an elevated IgG index and oligoclonal banding (Table 1).
Figure 1 Alignment of recovered peptides (marked in yellow) to the cerebrospinal fluid (CSF) transcriptome sequences. Green
highlighted letters show mutations from the germline sequence. Aquaporin-4 (AQP4)-specific sequences are marked in bold (for example, VH33),
CDR1, CDR2 and CDR3 parts are underlined. On average, greater than 80% of the translated CSF transcriptome sequences were identified by 2 or
more Ig peptide sequences.
Kowarik et al. Journal of Neuroinflammation  (2015) 12:19 Page 4 of 8Intrathecal production of AQP4-IgG (AQP4-AI ≥ 1.5)
was observed in patients ON10-03 and ON7-05 (Table 1).
Patient ON10-01 had an elevated AQP4-AI at 1.45
but the value did not exceed levels indicative of intra-




with matching IgG peptides
in CSF only
Subject Total AQP4-Specific Total AQP4-Specific
ON10-03 15/34 6/10 14/15 6/6
(44%) (60%) (93%) (100%)
ON09-03 26/79 6/14 14/26 5/6
(33%) (43%) (54%) (83%)
ON10-01 17/106 0/9 9/17 NR
(16%) (0%) (53%)
ON07-05 24/115 6/17 9/24 2/6
(21%) (35%) (37%) (33%)
ON08-08 18/49 2/3 10/18 0/3
(37%) (66%) (55%) (0%)
ON11-04 13/86 2/13 1/13 0/2
(15%) (15%) (8%) (0%)
TUM09-527 11/49 6/16 8/11 5/6
(22%) (38%) (73%) (83%)
Mean 27% 37% 53% 50%
95% CI 16 to37% 15 to- 58% 28 to 78% 3 to 97%
Abbreviations: AQP4 aquaporin-4, CSF cerebrospinal fluid, NR none recovered, 95% Cwith rituximab may have influenced peripheral antibody
production, a comparable number of serum peptides
could still be matched to AQP4-specific and nonspecific
CSF Ig transcripts. There was no relationship between the
timing of the lumbar puncture and the recovery of serumes identified by matching IgG peptides in serum and CSF
Transcriptome sequences
with matching IgG peptides
in CSF and serum
Transcriptome sequences
with matching IgG peptides
in serum only
Total AQP4-Specific Total AQP4-Specific
1/15 0/6 0/15 0/6
(7%) (0%) (0%) (0%)
11/26 1/6 1/26 0/6
(42%) (17%) (4%) (0%)
7/17 NR 1/17 NR
(41%) (6%)
11/24 2/6 4/24 2/6
(46%) (33%) (17%) (33%)
5/18 1/2 3/18 1/2
(28%) (50%) (17%) (50%)
3/13 1/2 9/13 1/2
(23%) (50%) (69%) (50%)
1/11 0/6 2/11 1/6
(9%) (0%) (18%) (17%)
28% 25% 18% 19%
13 to 33% 1 to 49% 0 to 63% 0 to 40%
I 95% confidence interval.
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underpowered to detect a difference.
The overlap of IgG transcriptomes and proteomes is
primarily in the CSF
IgG peptides that uniquely matched CSF transcriptome
sequences showed a common distribution among NMO
patients (Table 2). Surprisingly, IgG VH and VL peptides
matching CSF transcriptome sequences were recovered
more often in the CSF than the serum proteome. More
than 50% (range 8 to 93%) of the CSF IgG transcriptome
sequences were matched by peptides recovered exclu-
sively in the CSF IgG proteome. Approximately 28%
(range 7 to 46%) were found in both the CSF and serum
IgG proteome, and 18% (range 0 to 69%) were found ex-
clusively in the serum proteome. The majority of match-
ing peptides were found exclusively in the CSF proteome
in five of seven patients; in only one patient was the ma-
jority of recovered sequences found in the serum prote-
ome (Table 2). IgG peptides matching CSF transcriptome
sequences from AQP4-specific VH and VL chains showed
a similar average distribution: 50% (range 0 to 100%) were
recovered exclusively in the CSF IgG proteome, 25%
(range 0 to 50%) in both the serum and CSF compart-
ments, and 19% (range 0 to 50%) in the serum only. The
majority of IgG peptides matching AQP4-specific VH and
VL transcripts were recovered solely in the CSF in half of
the patients. The low number of AQP4-specific reference
sequences, however, limited this analysis (Table 2).
Overlap between the CSF IgG proteome and blood IgG
proteome
In NMO, pathogenic AQP4-IgG is presumed to passively
transit into the CNS where it initiates astrocyte injury and
secondary demyelination. Surprisingly, on average, only
28% of the IgG peptides matching CSF transcriptome se-
quences were recovered from both the CSF and serum of
the same individual, which may be the result of the limited
number of reference CSF transcripts. To complete a more
extensive analysis of the overlap between the CSF and
serum IgG proteomes, we searched the CSF and serum
IgG proteomes for identical, unique VH and VL peptides
independent of the transcriptome repertoires. By aligning
the peptides from patients’ serum and CSF to a random
human protein database (Swiss-Prot), we recovered on
average 995 VH (range 613 to 1,090) and 584 VL (range
299 to 1,166) CSF and serum Ig peptides per patient.
Further evaluation of these peptides for mutations from
germline identified 59 unique (non-germline) IgG pep-
tides in 5 out of 7 patients. No common unique IgG
peptides were identified in different patients. In contrast
to expectations, only 45% (range 0 to 77.8%) of the unique
VH or VL peptides were found in both the CSF and serum
compartments. Twenty-nine percent (range 11.1 to 52.9%)of the unique IgG peptides were found exclusively in the
CNS compartment, 26% (range 0 to 75%) in the peripheral
compartment only.
Discussion
The detection of AQP4 autoantibodies has been shown
to be a highly specific marker for NMO and AQP4-IgG
plays a direct role in disease pathology. However, it is
still unclear, whether CNS AQP4-IgG is primarily pro-
duced by peripheral plasma cells and passively leaks into
the CNS through an open blood-brain barrier (BBB) or
is generated in part by local CNS B cells. To date, sero-
logic studies have favored a passive influx of AQP4-IgG
from serum to CNS: the CSF:serum ratio of AQP4-IgG
is approximately 1:500 [6] and standard metrics indica-
tive of intrathecal AQP4-IgG synthesis are positive in
only a small fraction of patients [9].
In this study, we show that the overlap between the
CSF IgG transcriptome and proteome in NMO patients
was found primarily, but not exclusively, within the CSF
IgG fraction following acute exacerbations. These data
indicate that CSF plasma cells in NMO contribute to the
production of CSF AQP4-IgG and a significant fraction
of the IgG idiotypes are unique to or highly enriched
within the CNS compartment. The concurrent presence
of many matching peptides in the CSF and serum pro-
teomes indicates that some of the intrathecal plasma
cells originate from memory B cells that had previously
differentiated and populated peripheral plasma cell niches.
Analyses of the overlap between the CSF and serum IgG
peptides, independent of the CSF B cell transcriptomes,
also reveals that a significant fraction of intrathecal IgG
is unique to the CSF. Similar distributions were ob-
served for AQP4-specific VH and VL peptide sequences.
The data contrast with the expected results of a passive
influx of serum AQP4-IgG, where a near complete over-
lap of serum and CSF IgG would be anticipated. Indeed,
in our analysis, CSF metrics indicated a dysfunction of
the blood-CSF barrier in only two of seven patients
(Table 1).
Interestingly, approximately 20% of CSF VH trans-
cripts matched only serum Ig peptides. The absence of
overlap between these CSF B cell transcripts and the
CSF Ig proteome could result from methodological limi-
tations. While there is no data on the sensitivity and spe-
cificity of similar analyses [20,21], the high quality of the
peptide sequences on mass spectroscopy and the high
fidelity of the PCR transcripts lower concerns regarding
low specificity. Indeed, the reproduction of functional
AQP4-specific divalent IgG from the transcriptome
sequences is a testament to the high specificity of the
methods. In addition, it is possible that certain intra-
thecal B cells might not produce large amounts of IgG
or their product may be sequestered in CNS tissue.
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relationship between BBB disruption and CSF AQP4-
IgG. Jarius and colleagues [10] noted an association be-
tween AQP4-IgG CSF positivity and dysfunction of the
blood-CSF barrier; however, Dujmovic and colleagues
[8] noted no correlation between AQP4-IgG titers and
QAlbumin. These results suggest that the extent of BBB
disruption in active NMO may not be as global as antici-
pated and, dependent on the lesion localization and vol-
ume, QAlbumin might not be a sensitive enough marker
in NMO [9]. Additionally, the entry of AQP4-IgG into
the CNS may not require profound BBB permeability.
While our recovery of IgG peptides matching CSF VH
and VL transcripts was lower than in prior analyses in
MS patients [20,21], there is no significant indication
that the limited sampling skewed our results. Similar
distributions were observed for both total transcripts
and AQP4-specific transcripts (Table 2), and the overlap
of the CSF and serum IgG proteomes demonstrated that
a substantial fraction of intrathecal IgG peptides were
exclusive to the CNS compartment.
The combined proteomic and transcriptome analysis
of CSF IgG in NMO patients suggests that CNS AQP4-
IgG is a product of both passive transit from circulating
serum IgG and intrathecal plasmablasts and plasma cells
(Figure 2). Approximately half of the unique germline-
mutated IgG peptides in the CSF can be matched to IgG
peptides in the serum, indicating that a large component
of AQP4-IgG likely arises from passive transfer. Never-
theless, antibody secreting B cells in the CSF produce a
measurable portion of CSF IgG and AQP4-IgG idiotypes,
and the majority of those sequences cannot be matched to
the serum proteome, implying an emergent population ofFigure 2 Sources of cerebrospinal fluid (CSF) aquaporin-4 (AQP4)-IgG
specific to the CSF, while 70% are detected in serum. AQP4-IgG produced
intrathecal AQP4-IgG.expanded CSF B cells is present that has not populated
peripheral plasma cell niches. In prior studies, recognition
of the frequency of AQP4-IgG production in the CNS of
active NMO patients may have been masked by the rela-
tive insensitivity of standard laboratory measures used to
determine QIgG index and oligoclonal banding. These
measures may also be skewed by aspects of NMO path-
ology (spinal cord edema and BBB dysfunction) that alter
biophysical parameters such as blood-CSF diffusion and
CSF flow. Furthermore, the passive transfer of serum IgG
into the CSF may obscure faint bands of intrathecally pro-
duced IgG on isoelectric focusing. Finally, a significant
fraction of the AQP4-IgG produced intrathecally may
remain bound to glial tissue [2]. Therefore, sensitive mo-
lecular immunologic and proteomic techniques may be
required to uncover the presence of intrathecal produc-
tion of AQP4-IgG in most cases.
How might AQP4-IgG producing B cells and serum
AQP4-IgG combine to initiate an NMO relapse? The
migration of AQP4-IgG producing B cells into the CSF
could be the initial step. Although AQP4 is highly ex-
pressed on perivascular astrocyte foot processes, the
possibility that the limited fraction of circulating serum
AQP4-IgG might initiate CNS injury is confronted by
several quandaries. AQP4-specific autoantibodies are only
a minor component of the total serum IgG fraction [3],
CSF AQP4 titers do not always correlate with QAlbumin
[7], CSF AQP4-IgG is rarely detected during disease
remission [9], and only 10% of NMO attacks concentrate
in CNS regions with a naturally open BBB. Lastly, AQP4-
IgG administered intravenously to animals fails to initiate
NMO-specific pathology in the absence of autoimmune
encephalomyelitis [2].. Approximately 30% of the unique intrathecal IgG peptides are
by CSF plasmablasts may contribute to the pathogenic pool of
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stress or infection may precipitate an influx of a suffi-
cient amount of circulating AQP4-IgG to induce as-
trocytic injury, an alternative explanation, based on our
transcriptome and proteome data, is that NMO lesion
formation is initiated following the transit of pathologic
AQP4-IgG producing B cells to the CNS. The exclusive
identification of the majority of the CSF Ig transcrip-
tome in the CSF Ig proteome indicates that CSF plasma-
blasts are composed, in part, of a novel B cell population
that might emerge during an acute exacerbation. In
NMO CSF, plasmablasts show a remarkable degree of
intraclonal diversity (reference [3] and unpublished data),
which further supports recent release from germinal
centers. The overlap observed between the CSF tran-
scriptome and serum Ig proteome indicates that some
intrathecal plasma cells are likely to have arisen from
memory B cells that had previously established long-
lived tissue-resident plasma cell clones. In situ produc-
tion of AQP4-IgG by these transiting cells may be suffi-
cient to produce local disruption of the BBB and facilitate
passive entry of serum AQP4-IgG, lesion propagation, and
clinical symptomatology.
In this study, the qualitative picture of the overlap
between the CSF IgG transcriptome and the CSF and
serum proteomes may have been limited by differences
in the concentration and diversity of CSF and serum
IgG, the small number of patients analyzed, and the tim-
ing of CSF analysis relative to relapse onset. In addition,
the proportion of sequences and peptides recovered may
not reflect their absolute number. Despite these caveats,
the overlap of the IgG proteome and transcriptome se-
quences remained consistent among patients and showed
evidence of both intrathecal AQP4-IgG production by
CNS B cell clones and passive influx of serum IgG.
Conclusions
In this study we show, that a fraction of intrathecal IgG
including AQP4-IgG is generated by an intrathecal B cell
population composed of both novel and peripherally-
derived B cell clones. The production of intrathecal
AQP4-IgG by CSF B cell clones indicates that future
treatment in NMO may need to address both periph-
eral and CNS B cell populations for acute and prophy-
lactic strategies [22-24].
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